Holen Sie sich die Stockscreener-App
3.26
1.81%
-0.06
Schlusskurs vom Vortag:
$3.32
Offen:
$3.22
24-Stunden-Volumen:
22,509
Relative Volume:
0.19
Marktkapitalisierung:
$8.16M
Einnahmen:
$960.60K
Nettoeinkommen (Verlust:
$-7.01M
KGV:
-1.226
EPS:
-2.659
Netto-Cashflow:
$-7.78M
1W Leistung:
-1.87%
1M Leistung:
-15.54%
6M Leistung:
-35.73%
1J Leistung:
-72.09%
1-Tages-Spanne:
$3.22
$3.31
1-Wochen-Bereich:
$3.22
$3.43
52-Wochen-Spanne:
$1.8301
$19.20
Soligenix Inc Stock (SNGX) Company Profile
Firmenname
Soligenix Inc
Sektor
Branche
Telefon
609-538-8200
Adresse
29 EMMONS DRIVE, PRINCETON
Vergleichen Sie SNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
3.26 | 8.16M | 960.60K | -7.01M | -7.78M | -11.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.01 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.55 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.66 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.62 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-28 | Herabstufung | Dawson James | Buy → Neutral |
| 2018-01-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Bestätigt | Maxim Group | Buy |
| 2017-07-17 | Eingeleitet | H.C. Wainwright | Buy |
Soligenix Inc Aktie (SNGX) Neueste Nachrichten
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PR Newswire
Soligenix (STU:DOA) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs - Nasdaq
Soligenix Advances Promising Treatments for Rare Diseases and Public Health Threats - Citybuzz
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusqueti - GuruFocus.com
Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial - Dermatology Times
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - The Malaysian Reserve
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Soligenix gains Hong Kong patent for synthetic hypericin - Investing.com India
Soligenix to Present at Upcoming Conferences - GuruFocus.com
Soligenix gains Hong Kong patent for synthetic hypericin By Investing.com - Investing.com Nigeria
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - Lelezard
Soligenix Invited to Present at Upcoming Investor Conferences - StockTitan
Soligenix secures amended loan terms with Pontifax Medison - Investing.com India
Soligenix secures amended loan terms with Pontifax Medison By Investing.com - Investing.com UK
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PR Newswire
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference - Marketscreener.com
A stock that deserves closer examination: Soligenix Inc (SNGX) - US Post News
Soligenix partners with Sterling to scale hypericin production By Investing.com - Investing.com Australia
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development - Research Tree
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… - Zacks Small Cap Research
Soligenix partners with Sterling to scale hypericin production - Investing.com India
Soligenix Announces Partnership with Sterling Pharma Solutions - Lelezard
Indo-Asian News Service-SOLIGENIX ANNOUNCES PARTNERSHIP WITH STERLING PHARMA SOLUTIONS - IANS India Pvt Ltd
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - cnhinews.com
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Finanzdaten der Soligenix Inc-Aktie (SNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):